Ytterbium Pentetate

CHEMBL2219546 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
566.4 g/mol
LogP
Phase
4

Ytterbium pentetate (169Yb-DTPA) is a radioactive chelate complex where the rare earth element ytterbium-169 is conjugated to diethylenetriaminepentaacetic acid (DTPA), used as a radiopharmaceutical for cisternography and evaluation of cerebrospinal fluid dynamics by intrathecal injection. The radiolabeled complex distributes through the CSF spaces and can be imaged with gamma camera or SPECT to detect CSF leaks, communicating hydrocephalus, and CSF flow obstruction. Its gamma emission profile makes it suitable for nuclear medicine CSF imaging.

الوزن الجزيئي

566,4000 g/mol

TPSA

196,00 Ų

آلية العمل

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.[Yb]

InChI

InChI=1S/C14H23N3O10.Yb/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);

Molecular Formula

C14H23N3O10Yb

HBD / HBA

5 / 13

الروابط القابلة للدوران

16

الذرات الثقيلة

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Ytterbium pentetate (169Yb-DTPA) is a radioactive chelate complex where the rare earth element ytterbium-169 is conjugated to diethylenetriaminepentaacetic acid (DTPA), used as a radiopharmaceutical for cisternography and evaluation of cerebrospinal fluid dynamics by intrathecal injection. The radiolabeled complex distributes through the CSF spaces and can be imaged with gamma camera or SPECT to detect CSF leaks, communicating hydrocephalus, and CSF flow obstruction. Its gamma emission profile makes it suitable for nuclear medicine CSF imaging.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Ytterbium Pentetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2219546. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 177638023. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.